Antibiotic Use and Resistance in Agriculture Sector: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Zeinab Breijyeh
,
Rafik Karaman

Possible new ways for the development of novel classes of antibiotics are discussed here, for which there is no pre-existing resistance in human bacterial pathogens. By utilizing research and technology such as nanotechnology and computational methods (such as in silico and Fragment-based drug design (FBDD)), there has been an improvement in antimicrobial actions and selectivity with target sites. Moreover, there are antibiotic alternatives, such as antimicrobial peptides, essential oils, anti-Quorum sensing agents, darobactins, vitamin B6, bacteriophages, odilorhabdins, 18β-glycyrrhetinic acid, and cannabinoids. Additionally, drug repurposing (such as with ticagrelor, mitomycin C, auranofin, pentamidine, and zidovudine) and synthesis of novel antibacterial agents (including lactones, piperidinol, sugar-based bactericides, isoxazole, carbazole, pyrimidine, and pyrazole derivatives) represent novel approaches to treating infectious diseases. Nonetheless, prodrugs (e.g., siderophores) have shown to be an excellent platform to design a new generation of antimicrobial agents with better efficacy against multidrug-resistant bacteria.

  • antibiotic
  • resistance
  • antimicrobial agents

1. Introduction

Prior to the turn of the 20th century, infectious diseases were the main contributor to high morbidity and mortality rates around the world [1]. The period of antibiotics, which saw the discovery and development of numerous antibacterial drugs, began with Fleming’s discovery of penicillin in 1929. Regrettably, the emergence of resistant strains was brought on by the overuse and careless use of antibiotics [2][3]. According to 2019 systemic analytic research, there were 4.95 million fatalities attributable to antimicrobial resistance (AMR). With 27.3 deaths per 100,000 people, western sub-Saharan Africa has the highest mortality rate, whereas Australasia has the lowest mortality rate with 6.5 deaths per 100,000 people [4]. Twelve families of bacteria have been identified by the World Health Organization (WHO) as the most dangerous to human health and have been divided into three priority groups: critical pathogens (Acinetobacter, Pseudomonas, and Enterobacteriaceae), high priority pathogens (Enterococcus faecium, Staphylococcus aureus, Helicobacter pylori, Campylobacter, Salmonella spp., Nisseria gonorrhoeae), and medium priority pathogens (Streptococcus pneumoniae, Shigella spp.) [5][6][7][8]. The presence of multidrug-resistant (MDR) ESKAPE pathogens (including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) and extensively drug-resistant (XDR) bacteria has rendered even the most effective drugs ineffective. Therefore, its necessary to develop novel strategies and approaches to overcome the problem of increasing AMR [9][10][11].

2. Antibiotic Classification

New antibiotic use methods should be implemented on a local and global level to combat resistance, and the development of novel treatments requires a thorough understanding of how antibiotics function. Table 1 summarizes how antibiotics produce their effects through a variety of mechanism of action. Antibiotic-mediated cell death is a complicated process that begins with a physical interaction between the medication and its particular target in bacteria, altering the bacterium’s biochemical, molecular, or ultrastructural levels. The development of DNA double-stranded DNA breaks, the halting of DNA-dependent RNA synthesis, cell envelop damage, protein mistranslation, and stress induction are only a few of the methods through which antibiotics can cause cell death [12]. Antimicrobial agents are divided into two categories on the basis of how they affect bacteria in a test tube: (1) bactericidal (kill bacteria) antibiotics such as β-lactams, glycopeptides, lipopeptides, rifamycins, aminoglycosides, and fluoroquinolones, and (2) bacteriostatic (prevent bacterial growth) antibiotics such as sulfonamides–trimethoprim and macrolides. Bacteriostatic substances can also be described as having a minimum bactericidal concentration (MBC) to minimum inhibitory concentration (MIC) ratio higher than four, and bactericidal substances when the MBC to MIC ratio is lower than or equal to four [13].
Table 1. List of antimicrobial agent and their mechanism of action.

Antibiotics Family

Mechanism of Action

Antibiotics

β-lactam

Binds to the serine active site of penicillin-binding proteins (PBPs) or the allosteric site in PBP2a to inhibit bacterial cell wall peptidoglycan transpeptidation [14][15].

Penicillins

Cephalosporins

Carbapenems

Monocyclic β-lactams

β-lactamase inhibitors (e.g., clavulanic acid)

(Figure 1)

Glycopeptides

Interacts with the membrane-bound lipid II precursor of peptidogly and can prevent peptidoglycan from being incorporated into an essential structural cell wall component [16].

Vancomycin

Teicoplanin

Telavancin

Dalbavancin

Oritavancin

(Figure 1)

Lipopeptide

Carries out their action by causing Gram-positive bacteria’s cell membrane integrity to be compromised, which results in cell death [17][18].

Polymyxins

Daptomycin

Amphomycin

Friulimicin

Ramoplanin

Empedopeptin

(Figure 2)

Rifamycins

RNA polymerase (RNAP) inhibitors are used to treat tuberculosis (TB) [19].

Rifampin

Rifabutin

Rifapentine

(Figure 3)

Aminoglycoside

By attaching to the 30S ribosome’s A-site on the 16S ribosomal RNA, they inhibit protein synthesis [20].

Streptomycin

Apramycin

Tobramycin

Gentamcin

Amikacin

Neomycin

Arbekacin

Plazomicin

(Figure 3)

Fluoroquinolones

Target DNA gyrase, topoisomerase IV, and topoisomerase type II to prevent bacteria from synthesizing DNA [21].

Nalidixic acid

Enoxacin

Norfloxacin

Ciprofloxacin

Ofloxacin

Lomefloxacin

Sparfloxacin

Grepafloxacin

Clinafloxacin

Gatifloxacin

Moxifloxacin

Gemifloxacin

Trovafloxacin

Garenoxacin

(Figure 4)

Sulfonamides–Trimethoprim

Sulfonamides interfere with the activity of the dihydropteroate synthase enzyme by competing with p-aminobenzoic acid (PABA) in the process of dihydrofolate production.The dihydrofolate reductase enzyme is inhibited by trimethoprim because it competes directly with it [22].

Sulfamethoxazole

Trimethoprim

(Figure 4)

Macrolides

Target the nascent peptide exit tunnel (NPET) of the bacterial 50S ribosomal subunit, which is responsible for the release of newly synthesized protein from the ribosome, ultimately preventing protein synthesis [23][24].

Erythromycin

Clarithromycin

Azithromycin

Fidaxomicin

Telithromycin

(Figure 4)

Tetracyclines

Bind to the small subunit’s decoding site and prevent bacterial protein synthesis [25][26].

Chlortetracycline

Oxytetracycline Tetracycline Demeclocycline

Doxycycline

Minocycline

Lymecycline

Meclocycline

Methacycline RolitetracyclineTigecycline

Omadacycline

Sarecycline

Eravacycline

(Figure 5)

Oxazolidinones

Block the translation sequence by interacting with the 50S subunit (A-site pocket) at the peptidyl transferase center (PTC) to inhibit protein synthesis [27].

Linezolid

Sutezolid

Eperezolid

Delpazolid

Tedizolid

Tedizolid phosphate Radezolid

TBI-223

(Figure 5)

Streptogramins

Inhibit protein synthesis during the elongation step by attaching to bacterial ribosomes [28]. The antibiotic has two unique structural groups (A and B) that cooperate to increase the affinity of group B in the nearby nascent peptide exit tunnel (NPET) when group A binds to the peptidyl transferase center (PTC) [29].

Quinupristin

Pristinamycin

Virginiamycin

(Figure 6)

Phenicoles

Inhibit protein synthesis by binding to the 50S ribosomal subunit [30].

Chloramphenicol

Thiamphenicol

Florfenicol

(Figure 6)

Lincosamides

Activate amino acid monomers by aminoacyl-tRNA, chain initiation, elongation, and termination of the formed polypeptides on the ribosome, which disrupts bacterial growth and death. These are only a few of the many processes that can be affected to prevent microbial protein synthesis [31].

Lincomycin

Clindamycin

(Figure 6)
Figure 1. Chemical structure of penicillins, cephalosporins, carbapenems, monocyclic β-lactams, clavulanic acid (β-lactamase inhibitors), vancomycin, teicoplanin, telavancin, dalbavancin, and oritavancin.
Figure 2. Chemical structure of polymyxins, daptomycin, amphomycin, friulimicin, ramoplanin, and empedopeptin.
Figure 3. Chemical structure of rifampin, rifabutin, rifapentine, streptomycin, apramycin, tobramycin, gentamycin, amikacin, neomycin, arbekacin, and plazomicin.
Figure 4. Chemical structure of nalidixic acid, enoxacin, norfloxacin, ciprofloxacin, ofloxacin, lomefloxacin, sparfloxacin, grepafloxacin, clinafloxacin, gatifloxacin, moxifloxacin, gemifloxacin, trovafloxacin, arenoxacin, sulfamethoxazole, trimethoprim, erythromycin, clarithromycin, azithromycin, fidaxomicin, and telithromycin.
Figure 5. Chemical structure of chlortetracycline, oxytetracycline, tetracycline, demeclocycline, doxycycline, minocycline, lymecycline, meclocycline, methacycline, rolitetracycline, tigecycline, omadacycline, sarecycline, eravacycline, linezolid, sutezolid, eperezolid, delpazolid, tedizolid, tedizolid phosphate, radezolid, and TBI-223.
Figure 6. Chemical structure of quinupristin, pristinamycin, virginiamycin, chloramphenicol, thiamphenicol, florfenicol, lincomycin, and clindamycin.

3. Antimicrobial Resistance

The World Health Organization (WHO) describes antimicrobial resistance as a natural phenomenon that happens when germs cease responding to antibiotics that they were previously susceptible to before. Resistance makes treating infections more difficult or impossible [8][32]. In bacteria, there are two types of resistance: acquired and natural [33]. Natural resistance can either be produced or intrinsic (expressed in a species without connection to horizontal gene transfer) (the natural bacterial genes are only expressed to resistance levels after exposure to an antibiotic). Contrarily, acquired resistance can develop after acquiring genetic material that already exhibits it through horizontal gene transfer (HGT) (transformation, transposition, and conjugation) or by causing a mutation in the cell’s DNA during replication [8][33][34]. Antimicrobial resistance mechanisms include drug inactivation, decreased intracellular drug concentration, and altered drug targets (Figure 7) [35][36]. One of the most significant mechanisms of acquired resistance is the change or degradation of antibiotics. Bacterial enzymes have the ability to alter a number of antibiotics, including aminoglycoside, chloramphenicol, and β-lactam [37][38]. By increasing efflux or decreasing influx, one can lower drug concentration [39]. Bacteria can develop a high level of inherent resistance owing to this method. Porin mutations in resistant strains alter the permeability of bacterial membranes, which reduces medication uptake into the cell. For instance, OprD, a particular porin in strains of P. aeruginosa, can result in a mutation for carbapenem resistance [40]. The Proteobacterial Antimicrobial Compound Efflux (PACE) superfamily, the Resistance Nodulation Division (RND) family, the Small Multidrug Resistance (SMR) superfamily, the Multidrug and Toxic Compound Extrusion (MATE) superfamily, and the ATP (adenosine triphosphate)-Binding Cassette (ABC) superfamily are the six families that make up the transmembrane proteins that make up efflux pumps [41][42]. The most prevalent efflux pumps in both Gram-positive and Gram-negative bacteria are MFS and RND pumps [39]. The medication target changing is another method of resistance. Examples include the resistance to glycopeptide and polymyxin antibiotics caused by enzymes that chemically alter components of the cell membrane necessary for antibiotic binding. Methyltransferases are another example of target modifying enzymes since they change the rRNA elements on the ribosome and thus become resistant to antibiotics including aminoglycoside, lincosamide, macrolide, streptogramin, and oxazolidinone [43]. Another phenomenon known as “target protection” occurs when an antibiotic target’s resistance protein protects it from antibiotic-induced inhibition (target protection protein). Tetracycline ribosomal protection proteins (TRPPs) are an illustration of this mechanism [44].
Figure 7. Mechanism of antimicrobial resistance which include reduce intracellular antibiotic concentration, antibiotic inactivation, and target site alteration.

4. Antibiotic Use and Resistance in Agriculture Sector

β-lactams, aminoglycosides, tetracyclines, macrolides, and other antibiotics with comparable modes of action to those used by humans are causing a lot of concern due to their possible side effects and risk management strategies [45]. Because medicines are available over the counter, their overuse, abuse, and misuse are linked to antibiotic resistance [46]. Antibiotic resistance is caused by the use of antibiotics in animals raised for food. Food safety and public health may suffer if antibiotic residues are found in products obtained from animals that are intended for human consumption [47][48][49]. Use of unnecessary antibiotics in animals for the purpose of promoting development, as well as waste products from veterinary care and livestock farming, human waste streams, and soil fertilization, can result in the release of antibiotics pollution into the environment. As a result, it is possible to think of the environment as a reservoir for antibiotics and bacteria that are resistant to antibiotics, and their resistance genes [45][50][51][52]. Reports that some bacterial infections in humans are brought on by animal pathogens (zoonotic pathogens) such as Salmonella spp., Staphylococcus spp., Yersinia enterocolitica, Enterococcus spp., Listeria monocytogenes, Campylobacter jejuni and Escherichia coli [53][54][55] have demonstrated that antibiotic resistance can be transmitted directly or indirectly from animal to human. To prevent antibiotic resistance and maintain the potency of the available antibiotics, a number of practices should be regulated for the prudent use of antibiotics in the clinical and agricultural sectors [56][57]. The demand for antibiotics to cure illnesses can be decreased by improving animal feed, waste management, and animals’ natural immunity. Moreover, using antibiotic alternatives including prebiotics, probiotic vaccines, and bacteriophages can help reduce the need for antibiotics [58][59][60].

This entry is adapted from the peer-reviewed paper 10.3390/antibiotics12030628

References

  1. Adedeji, W.A. The Treasure Called Antibiotics. Ann. Ib. Postgrad. Med. 2016, 14, 56–57.
  2. Breijyeh, Z.; Jubeh, B.; Karaman, R. Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. Molecules 2020, 25, 1340.
  3. Karaman, R.; Jubeh, B.; Breijyeh, Z. Resistance of Gram-Positive Bacteria to Current Antibacterial Agents and Overcoming Approaches. Molecules 2020, 25, 2888.
  4. Antimicrobial Resistance, C. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022, 399, 629–655.
  5. Asokan, G.V.; Ramadhan, T.; Ahmed, E.; Sanad, H. WHO Global Priority Pathogens List: A Bibliometric Analysis of Medline-PubMed for Knowledge Mobilization to Infection Prevention and Control Practices in Bahrain. Oman Med. J. 2019, 34, 184–193.
  6. WHO. Priority Pathogens List of Antibiotic-Resistant Bacteria for Which New Antibiotics are Urgently Needed; WHO: Geneva, Switzerland, 2017.
  7. Shrivastava, S.; Shrivastava, P.; Ramasamy, J. World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. J. Med. Soc. 2018, 32, 76.
  8. Mancuso, G.; Midiri, A.; Gerace, E.; Biondo, C. Bacterial Antibiotic Resistance: The Most Critical Pathogens. Pathogens 2021, 10, 1310.
  9. Mulani, M.S.; Kamble, E.E.; Kumkar, S.N.; Tawre, M.S.; Pardesi, K.R. Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review. Front. Microbiol. 2019, 10, 539.
  10. De Oliveira, D.M.P.; Forde, B.M.; Kidd, T.J.; Harris, P.N.A.; Schembri, M.A.; Beatson, S.A.; Paterson, D.L.; Walker, M.J. Antimicrobial Resistance in ESKAPE Pathogens. Clin. Microbiol. Rev. 2020, 33, e00181-19.
  11. Qadri, H.; Shah, A.H.; Mir, M. Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes. Curr. Drug Targets 2021, 22, 1424–1436.
  12. Kohanski, M.A.; Dwyer, D.J.; Collins, J.J. How antibiotics kill bacteria: From targets to networks. Nat. Rev. Microbiol. 2010, 8, 423–435.
  13. Calhoun, C.; Wermuth, H.R.; Hall, G.A. Antibiotics; StatPearls: Treasure Island, FL, USA, 2022.
  14. Bush, K.; Bradford, P.A. beta-Lactams and beta-Lactamase Inhibitors: An Overview. Cold Spring Harb. Perspect. Med. 2016, 6, a025247.
  15. Eyler, R.F.; Shvets, K. Clinical Pharmacology of Antibiotics. Clin. J. Am. Soc. Nephrol. Cjasn 2019, 14, 1080–1090.
  16. Blaskovich, M.A.T.; Hansford, K.A.; Butler, M.S.; Jia, Z.; Mark, A.E.; Cooper, M.A. Developments in Glycopeptide Antibiotics. Acs Infect. Dis. 2018, 4, 715–735.
  17. Bionda, N.; Pitteloud, J.P.; Cudic, P. Cyclic lipodepsipeptides: A new class of antibacterial agents in the battle against resistant bacteria. Future Med. Chem. 2013, 5, 1311–1330.
  18. Schneider, T.; Muller, A.; Miess, H.; Gross, H. Cyclic lipopeptides as antibacterial agents—Potent antibiotic activity mediated by intriguing mode of actions. Int. J. Med. Microbiol. Ijmm 2014, 304, 37–43.
  19. Adams, R.A.; Leon, G.; Miller, N.M.; Reyes, S.P.; Thantrong, C.H.; Thokkadam, A.M.; Lemma, A.S.; Sivaloganathan, D.M.; Wan, X.; Brynildsen, M.P. Rifamycin antibiotics and the mechanisms of their failure. J. Antibiot. 2021, 74, 786–798.
  20. Krause, K.M.; Serio, A.W.; Kane, T.R.; Connolly, L.E. Aminoglycosides: An Overview. Cold Spring Harb. Perspect. Med. 2016, 6, a027029.
  21. Pham, T.D.M.; Ziora, Z.M.; Blaskovich, M.A.T. Quinolone antibiotics. Medchemcomm 2019, 10, 1719–1739.
  22. Kemnic, T.R.; Coleman, M. Trimethoprim Sulfamethoxazole; StatPearls: Treasure Island, FL, USA, 2022.
  23. Patel, P.H.; Hashmi, M.F. Macrolides; StatPearls: Treasure Island, FL, USA, 2022.
  24. Vazquez-Laslop, N.; Mankin, A.S. How Macrolide Antibiotics Work. Trends Biochem. Sci. 2018, 43, 668–684.
  25. Rusu, A.; Buta, E.L. The Development of Third-Generation Tetracycline Antibiotics and New Perspectives. Pharmaceutics 2021, 13, 2085.
  26. Nguyen, F.; Starosta, A.L.; Arenz, S.; Sohmen, D.; Donhofer, A.; Wilson, D.N. Tetracycline antibiotics and resistance mechanisms. Biol. Chem. 2014, 395, 559–575.
  27. Foti, C.; Piperno, A.; Scala, A.; Giuffre, O. Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects. Molecules 2021, 26, 4280.
  28. Bonfiglio, G.; Furneri, P.M. Novel streptogramin antibiotics. Expert Opin. Investig. Drugs 2001, 10, 185–198.
  29. Li, Q.; Pellegrino, J.; Lee, D.J.; Tran, A.A.; Chaires, H.A.; Wang, R.; Park, J.E.; Ji, K.; Chow, D.; Zhang, N.; et al. Synthetic group A streptogramin antibiotics that overcome Vat resistance. Nature 2020, 586, 145–150.
  30. Oong, G.C.; Tadi, P. Chloramphenicol; StatPearls: Treasure Island, FL, USA, 2022.
  31. Spizek, J.; Rezanka, T. Lincosamides: Chemical structure, biosynthesis, mechanism of action, resistance, and applications. Biochem Pharm. 2017, 133, 20–28.
  32. WHO. World Health Organization Ten Threats to Global Health in 2019; WHO: Geneva, Switzerland, 2019.
  33. Reygaert, W.C. An overview of the antimicrobial resistance mechanisms of bacteria. Aims Microbiol. 2018, 4, 482–501.
  34. Francine, P. Systems Biology: New Insight into Antibiotic Resistance. Microorganisms 2022, 10, 2362.
  35. Chancey, S.T.; Zahner, D.; Stephens, D.S. Acquired inducible antimicrobial resistance in Gram-positive bacteria. Future Microbiol. 2012, 7, 959–978.
  36. Mahon, C.R.; Lehman, D.C. Textbook of Diagnostic Microbiology—E-Book; Elsevier Health Sciences: USA, 2022.
  37. Sultan, I.; Rahman, S.; Jan, A.T.; Siddiqui, M.T.; Mondal, A.H.; Haq, Q.M.R. Antibiotics, Resistome and Resistance Mechanisms: A Bacterial Perspective. Front. Microbiol. 2018, 9, 2066.
  38. Ndagi, U.; Falaki, A.A.; Abdullahi, M.; Lawal, M.M.; Soliman, M.E. Antibiotic resistance: Bioinformatics-based understanding as a functional strategy for drug design. Rsc Adv. 2020, 10, 18451–18468.
  39. Kabra, R.; Chauhan, N.; Kumar, A.; Ingale, P.; Singh, S. Efflux pumps and antimicrobial resistance: Paradoxical components in systems genomics. Prog. Biophys. Mol. Biol. 2019, 141, 15–24.
  40. Ogawara, H. Comparison of Antibiotic Resistance Mechanisms in Antibiotic-Producing and Pathogenic Bacteria. Molecules 2019, 24, 3430.
  41. Spengler, G.; Kincses, A.; Gajdacs, M.; Amaral, L. New Roads Leading to Old Destinations: Efflux Pumps as Targets to Reverse Multidrug Resistance in Bacteria. Molecules 2017, 22, 468.
  42. Munita, J.M.; Arias, C.A. Mechanisms of Antibiotic Resistance. Microbiol. Spectr. 2016, 4, 481–511.
  43. Schaenzer, A.J.; Wright, G.D. Antibiotic Resistance by Enzymatic Modification of Antibiotic Targets. Trends Mol. Med. 2020, 26, 768–782.
  44. Wilson, D.N.; Hauryliuk, V.; Atkinson, G.C.; O’Neill, A.J. Target protection as a key antibiotic resistance mechanism. Nat. Rev. Microbiol. 2020, 18, 637–648.
  45. Manyi-Loh, C.; Mamphweli, S.; Meyer, E.; Okoh, A. Antibiotic Use in Agriculture and Its Consequential Resistance in Environmental Sources: Potential Public Health Implications. Molecules 2018, 23, 795.
  46. Ayukekbong, J.A.; Ntemgwa, M.; Atabe, A.N. The threat of antimicrobial resistance in developing countries: Causes and control strategies. Antimicrob. Resist. Infect. Control 2017, 6, 47.
  47. Finley, R.L.; Collignon, P.; Larsson, D.G.; McEwen, S.A.; Li, X.Z.; Gaze, W.H.; Reid-Smith, R.; Timinouni, M.; Graham, D.W.; Topp, E. The scourge of antibiotic resistance: The important role of the environment. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2013, 57, 704–710.
  48. Guetiya Wadoum, R.E.; Zambou, N.F.; Anyangwe, F.F.; Njimou, J.R.; Coman, M.M.; Verdenelli, M.C.; Cecchini, C.; Silvi, S.; Orpianesi, C.; Cresci, A.; et al. Abusive use of antibiotics in poultry farming in Cameroon and the public health implications. Br. Poult. Sci. 2016, 57, 483–493.
  49. Baynes, R.E.; Dedonder, K.; Kissell, L.; Mzyk, D.; Marmulak, T.; Smith, G.; Tell, L.; Gehring, R.; Davis, J.; Riviere, J.E. Health concerns and management of select veterinary drug residues. Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc. 2016, 88, 112–122.
  50. Maron, D.F.; Smith, T.J.; Nachman, K.E. Restrictions on antimicrobial use in food animal production: An international regulatory and economic survey. Glob. Health 2013, 9, 48.
  51. Gillings, M.R. Evolutionary consequences of antibiotic use for the resistome, mobilome and microbial pangenome. Front. Microbiol. 2013, 4, 4.
  52. Dolliver, H.; Gupta, S. Antibiotic losses in leaching and surface runoff from manure-amended agricultural land. J. Environ. Qual. 2008, 37, 1227–1237.
  53. Davies, J.; Davies, D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. Mmbr 2010, 74, 417–433.
  54. Phillips, I.; Casewell, M.; Cox, T.; De Groot, B.; Friis, C.; Jones, R.; Nightingale, C.; Preston, R.; Waddell, J. Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data. J. Antimicrob. Chemother. 2004, 53, 28–52.
  55. Marshall, B.M.; Levy, S.B. Food animals and antimicrobials: Impacts on human health. Clin. Microbiol. Rev. 2011, 24, 718–733.
  56. Moudgil, P.; Bedi, J.S.; Moudgil, A.D.; Gill, J.P.S.; Aulakh, R.S. Emerging issue of antibiotic resistance from food producing animals in India: Perspective and legal framework. Food Rev. Int. 2017, 34, 447–462.
  57. Sharma, C.; Rokana, N.; Chandra, M.; Singh, B.P.; Gulhane, R.D.; Gill, J.P.S.; Ray, P.; Puniya, A.K.; Panwar, H. Antimicrobial Resistance: Its Surveillance, Impact, and Alternative Management Strategies in Dairy Animals. Front. Vet. Sci. 2017, 4, 237.
  58. Ying, G.G.; He, L.Y.; Ying, A.J.; Zhang, Q.Q.; Liu, Y.S.; Zhao, J.L. China Must Reduce Its Antibiotic Use. Environ. Sci. Technol. 2017, 51, 1072–1073.
  59. Marquardt, R.R.; Li, S. Antimicrobial resistance in livestock: Advances and alternatives to antibiotics. Anim. Front. Rev. Mag. Anim. Agric. 2018, 8, 30–37.
  60. Rahman, M.R.T.; Fliss, I.; Biron, E. Insights in the Development and Uses of Alternatives to Antibiotic Growth Promoters in Poultry and Swine Production. Antibiotics 2022, 11, 766.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback